Introduction {#S1}
============

Schistosomiasis, as one of the most severe infectious diseases and the most devastating tropical parasitic disease, is caused by *schistosoma* worm via the direct contact with the water containing cercaria ([@B31]; [@B46]; [@B15], [@B16]). This disease is endemic in tropical and sub-tropical areas including 76 countries in Asia, Africa, and Latin America. In the worldwide, it was estimated that about 779 million individuals were at risk of infection, which led the loss of an estimated 4.5 million disability-adjusted life years ([@B30]; [@B18], [@B17]). Acute infection was the most serious hazard for human beings, it can cause fever, gastrointestinal symptom, liver and spleen enlargement. And the advanced schistosomiasis occur when the treatment incomplete or delayed ([@B26]), which can further cause cardiopulmonary diseases ([@B41]), bladder cancer ([@B40]), and some other fatal cancers ([@B13]; [@B12]).

Currently, the Kato-Katz technique by detecting eggs in feces under microscope and the immunological approaches by detecting soluble antigens secreted from the hatching-eggs via the antigen-antibody reaction were the two main methods for diagnosis, however, none of these two methods is suitable for the early diagnosis ([@B47]; [@B19]). In addition, considering the frequent false negative and positive results these methods produce, there is an urgent need to develop new diagnosis method. Previous studies already showed the schistosomiasis caused alterations at the transcription and protein levels ([@B30]; [@B35]; [@B10]; [@B44]), however, these changes have not been explored in the early stage of the infection. Therefore, comprehensively study the dynamic response of hosts with schistosomiasis will help us the better understanding of the mechanisms underlying the disease progression and shed light on the development of more suitable tools for early diagnosis of schistosomiasis.

Metabolites in body fluid could manifest the status of health or disease to a certain extent, and also could be used as clue in diagnosis and treatment of diseases. Metabolomics, is concerned with the metabolite composition of biological systems and its dynamic responses to both endogenous and exogenous stimuli are particularly suitable for exploring the holistic metabolic responses to infections ([@B43]). For the past decade, metabolomics, as an emerging technology, has been demonstrated to be a very powerful tool in the study of the host metabolic responses to infections by parasites ([@B22]; [@B27]). Currently, for most of the metabolomics studies related to parasitic infection, capillary electrophoresis mass spectrometry (CE-MS), and nuclear magnetic resonance (NMR) were the most widely used technologies for the analysis of the dynamic metabolite changes in this field ([@B9]; [@B22]; [@B33]). Previous works have demonstrated that parasitic infection is related with disrupted pathway of energy metabolism, immune responses, glucose uptake and metabolism, and gut bacteria metabolism. However, these studies were mostly based on the well-established late-stage *schistosoma* infection model. Up to date, only one investigation based on the combination of NMR spectroscopy and multivariate data analysis has been carried out to study the time-course metabolomic changes over 5 weeks in the *Schistosoma japonicum* infected mice model ([@B47]). As one of the most popular technologies used in metabolomics field, NMR has several advantages over other technologies which include non-destructive sample preparation, suitable for structural elucidation, good reproducibility, and quantitative aspects. However, the analysis of NMR spectra of complex mixtures has traditionally been limited. Due to its relatively low sensitivity, NMR technology is not appropriate for comprehensive metabolite profiling of large number of low-abundance metabolites, and may lose some meaningful metabolites. Compared to NMR technology, MS has many important advantages such as high sensitivity, high-throughput, capability of the identification of the components present in complex biological samples, and the capacity of identification of unknown and unexpected compounds. All of the above mentioned advantages make MS a very powerful technology for detecting hundreds of compounds in metabolomics field. Moreover, MS, when combined with high-performance liquid chromatography, particularly with ultra-high-performance liquid chromatography (UHPLC-MS), can enable metabolomics analysis with much higher resolution, and better analytical flexibility ([@B4]; [@B52]). In this study, a LC-MS-based metabolomics method was established and was applied to study metabolic changes in the serum from the *S. japonicum* infected mice over the time course of 5 weeks. Thus, our study is aimed to explore the mechanisms of host-parasite interaction during the disease process and pave the way for the development of an early diagnosis tool for schistosomiasis.

Materials and Methods {#S2}
=====================

Experimental Animals {#S2.SS1}
--------------------

All animal studies were performed in accordance with the National Institutes of Health (NIH) guide for the Care and Use of Laboratory Animals. The experimental procedures were approved by the Ethical Committee for the Experimental Use of Animals at Jiangsu institute of Parasitic Diseases (Wuxi, China). Fifty-three BALB/c female mice (120--130 *g*) at the age of 5 weeks were purchased from Yangzhou university (Yangzhou, China). Six mice per cage were provided by standard laboratory conditions (temperature of 20--25°C, relative humidity of 55--65%, and 12 h/12 h light/dark cycle) with free access to water and standard chow for 1 week before modeling. The mice were randomly divided into six groups, including control group and model groups. The model groups were infected with 40 cercariae of *S. japonicum* through the shaved abdominal skin for 30 min and no other treatment or manipulation of the animals was involved, and the control group was exposed to physiological saline at similarly shaved abdominal skin and raised at the same time. The blood samples were collected from tail vein at 0, 1, 2, 3, 4, and 5 weeks after infection with *S. japonicum*, respectively.

Chemicals and Reagents {#S2.SS2}
----------------------

HPLC-grade methanol and acetonitrile (ACN) were purchased from Merk (Darmstadt, Germany). Formic acid was obtained from Fluka (Buchs, Switzerland). Ultrapure water was prepared with a Milli-Q water purification system (Millipore, Bedford, MA, United States).

Sample Collection and Preparation {#S2.SS3}
---------------------------------

The blood samples were taken from tail venous and collected in a 1.5 mL tube at room temperature for 1 h, then centrifuged at 4,000 rpm for 15 min. The supernatant (serum) was aliquoted and stored at −80°C until LC-MS analysis. All the experiments were operated at the same time every week. 300 μL methanol was added to each 100 μL aliquot of serum. After vigorous shaking for 1 min, the mixtures were centrifuged at 13,000 rpm for 15 min at 4°C to precipitate the protein. Then, the serum was transferred to a sampling vial, and transferred to an autosampler vial and an aliquot of 4 μL was injected for LC-MS analysis. An in-house quality control (QC) was prepared by pooling and mixing the same volume of each sample. The QC sample was run six times prior to the start of the analytical run to "condition" the system and analyzed after every 8 samples to check for system stability.

Global Metabolite Profiling {#S2.SS4}
---------------------------

UHPLC analysis was performed on Agilent 1290 Infinity LC system (Agilent, Germany). An ACQUITY UPLC HSS T3 column (2.1 mm × 100 mm, 1.7 μm, Waters, Milford, MA, United States) was used to separate the serum samples at 45°C with a flow rate of 0.4 ml/min. The mobile phase consisted of A, 0.1% formic acid and B, ACN modified with 0.1% formic acid. The gradient program was as follows: 100% A at 0--2 min, 100%--85% A at 2--10 min, 85%--70% A at 10--14 min, 70%--5% A at 14--17 min, 5% A at 17--19 min, and 5%-100% A at 19--20 min, followed by a 5-min column re-equilibration.

An Agilent 6530 Accurate Mass Quadrupole Time-of-Flight (Q-TOF) mass spectrometer (Agilent, Santa Clara, CA, United States) was adapted to detect ion peaks, and the detection was operated at a negative ion mode. The cone gas was nitrogen with a flow rate of 11 L/h. The following detection parameters were used: fragment voltage, 120 V; capillary voltage, 3.5 kV; gas temperature, 350°C; and source temperature, 120°C. The full MS scan mode was monitored at the mass range of 50--1000 m/z. In the analyzing process, 10 mM purine (m/z 121.0508), and 2 mM hexakis phosphazinen (m/z 922.0097) were used as internal standards to guarantee mass accuracy and reproducibility. The centroid data were collected from the instrument. Subsequently, a MS/MS experiment was performed and the experiment parameters were set as follows: MS spectrum acquisition rate, 2 spectra/s, MS/MS spectrum acquisition rate, 0.5 spectra/s; and medium isolation window, 4 m/z; and collision energy, 20 V.

Data Handling {#S2.SS5}
-------------

Data processing used the method previously published by our group with minor modification. The raw data in instrument specific format (.d) were converted to common data format (.mzData) files using a conversion software program (file converter program available in Agilent MassHunter Qualitative sofware), in which the isotope interferences were eliminated. The program XCMS (version, 1.40.0) was used for non-linear alignment of the data in the time domain and automatic integration and extraction of the peak intensities. XCMS parameters were default settings (major default parameters: profmethod = bin; method = matched Filter; and step = 0.1) except for the following: full width at half maximum (FWHM) = 8, bandwidth (bw) = 10, and snthresh = 5, due to narrower peaks obtained by the use of the column packed with 1.7 μm particles. The variables presenting in at least 80% of either group were extracted, and the variables with a retention time less than 0.5 min (near to the dead time) were excluded due to a high degree of ion suppression that they suffered. The resulting three-dimensional matrix, including retention time and *m/z* pairs (variable indices), sample names (observations), and normalized ion intensities (variables), was exported to multivariate data analysis. The normalized data was introduced to SIMCA-P V12.0 (Umetrics, Sweden) for principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) after mean-centering and pareto scaling, a technique that increased the importance of low abundance ions without significant amplification of noise. The quality of the models was evaluated with the relevant *R*^2^ and *Q*^2^. One-way ANOVA was performed to reveal the statistical differences in the significance of variation among control (0 week) and post-infection (1, 2, 3, 4, and 5 week) groups. And the Tukey *post hoc* test was applied for comparisons of multiple groups. The differences were considered significant when *p* \< 0.05 and VIP \> 1.

Results {#S3}
=======

Identification of Infected Animals {#S3.SS1}
----------------------------------

Stool samples were examined by the Kato--Katz thick smear method every week after infection, all the animal in the model group were recognized as infection successful once egg found in the stool ([@B39]). Furthermore, the eggs of feces were also collected and counted from all the infected mice after 6 weeks post-infection, which showed 4083.94 ± 474.94 eggs per gram of feces. All the experiments were carried out by the skilled technicians.

System Stability Assessment {#S3.SS2}
---------------------------

To validate the stability of the established method, an in-house QC sample was prepared by pooling and mixing the same volume of each sample. In order to present the real system state, QC data were introduced to SIMCA-P V12.0 for PCA after mean-centering and pareto scaling, as shown in [Figure 1](#F1){ref-type="fig"}, all the QC samples were gathered together, which is a proof of system stability. The results indicated that the method was reliable for the subsequent analysis. In addition, the control and post-infection groups at different weeks were shown for some degree separation trend. The metabolic profiles of mice serum had an association with the time course of *S. japonicum* infection and disease progression. The metabolic profiles obtained from the infected mice deviated from the corresponding controls from the first week post-infection onwards and such separations became more obvious as disease progression. In order to identify the metabolites associated with such separations, we further compared the metabolic profiles obtained from the infected mice and corresponding controls for all matched time points, including the pre-infection day, week 1, 2, 3, 4, and 5 post-infection.

![PCA score plot of the UHPLC/TOF-MS spectral from control group (0 w), post-infection group (1, 2, 3, 4, and 5 w), and QC group. Each color represents a group, and each point represents a sample. The farther the distance between the samples spots is, the more significant the difference between the samples is.](fmicb-11-01517-g001){#F1}

Multivariate Statistical Analysis of Serum Metabolic Profiles {#S3.SS3}
-------------------------------------------------------------

The normalized data sets contained 1060 ions. To determine whether the metabolite fingerprints in serum deferred between the control and post-infection mice, we evaluated separation between the control and post-infection mice using supervised PLS-DA. The obvious separation was achieved between post-infection groups and control group, which were shown in [Figures 2A--E](#F2){ref-type="fig"}. To validate the model, permutation tests with 200 iterations were further performed. These permutation tests compared the goodness of fit of the original model with the goodness of fit of randomly permuted models. As shown in [Figures 2K--O](#F2){ref-type="fig"}, the validation plots indicates that the original models are valid. The criteria for validity are as follows: all the permuted *R*^2^ (cum) and Q*^2^* (cum) values to the left are lower than the original point to the right, and the blue regression line of the *Q*^2^ (cum) points has a negative intercept.

![The results of multivariate data analysis. PLS-DA score map derived from UHPLC-Q-TOFMS spectra \[**(A)** concerning 0 w and 1 w post-infection groups, **(B)** concerning 0 w and 2 w post-infection groups, **(C)** concerning 0 w and 3 w post-infection groups, **(D)** concerning 0 w and 4 w post-infection *n* groups, and **(E)** concerning 0 w and 5 w post-infection groups\], red color represents post-infection groups (1, 2, 3, 4, and 5 w), block color represents control group; S-VIP plot \[**(F)** concerning 0 w and 1 w post-infection groups, **(G)** concerning 0 w and 2 w post-infection groups, **(H)** concerning 0 w and 3 w post-infection groups, **(I)** concerning 0 w and 4 w post-infection groups, and **(J)** concerning 0 w and 5 w post-infection groups\], red color represents variable importance in the projection, block color represents *p*(corr) vaule; Validation plot obtained from 200 permutation tests \[**(K)** concerning 0 w and 1 w post-infection groups, **(L)** concerning 0 w and 2 w post-infection groups, **(M)** concerning 0 w and 3 w post-infection groups, **(N)** concerning 0 w and 4 w post-infection groups, **(O)** concerning 0 w and 5 w post-infection groups\], green and blue colors represent *R*^2^ and *Q*^2^ values, respectively, used to evaluate whether the model is over-fitting.](fmicb-11-01517-g002){#F2}

Identification of Differential Serum Metabolites for *S. japonicum* Infection {#S3.SS4}
-----------------------------------------------------------------------------

Metabolites were carefully screened before being approved as potential biomarkers. First, significant original variables were extracted from the S-VIP plot, which is a covariance-correlation-based procedure, and thus the risk of false positives in metabolite selection was reduced. The S-VIP plot ([Figures 2F--J](#F2){ref-type="fig"}), derived from the first component of the combined model, explains most of the variables in data set, in which the ions furthest away from the origin contribute significantly to the clustering of the two groups and may be regarded as potential biomarkers. Next, the variable importance for projection (VIP) indicating the importance of variables was applied to filter the important metabolites in the model. The most important 51, 54, 47, 58, 49 variables were first selected according to their VIP value when compared samples of 1, 2, 3, 4, and 5 week post-infection to those of 0 w, respectively.

One-way ANOVA were performed as the final testing procedure, and the critical *p*-value was set to 0.05 for significantly differential variables. Following the criterion above, 45, 44, 41, 49, and 48 metabolite ions were selected, respectively, as potential biomarkers related to *S. japonicum* infection at different time points. The detailed data was listed in [Table 1](#T1){ref-type="table"}.

###### 

Summary of the potential biomarkers related to *S. japonicum* infection.

  **No.**   **Compound**                           **VIP^a^**   ***P* value^a^**   **VIP^b^**   ***P* value^b^**   **VIP^c^**   ***P* value^c^**   **VIP^d^**   ***P* value^d^**   **VIP^e^**   ***P* value^e^**
  --------- -------------------------------------- ------------ ------------------ ------------ ------------------ ------------ ------------------ ------------ ------------------ ------------ ------------------
  1         9(S)-HpODE                             1.04         \< 0.001                                                                           1.24         \< 0.001           1.00         \< 0.001
  2         D-Glucuronic acid                      1.53         \< 0.001           1.55         \< 0.001           1.46         \< 0.001           1.88         \< 0.001           1.35         \< 0.001
  3         α-D-Glucose                            5.74         0.029              6.03         0.016              6.24         0.002                                              6.10         0.005
  4         19-Oxotestosterone                     1.43         \< 0.001                                                                           1.66         \< 0.001           1.32         \< 0.001
  5         1-Methylinosine                        1.17         \< 0.001           1.44         \< 0.001           1.20         \< 0.001           1.75         \< 0.001           1.22         \< 0.001
  6         3-Hydroxyphenyllactate                 3.31         0.028              3.50         0.015              3.60         0.002                                              3.58         0.005
  7         3-Sulfinoalanine                       1.03         0.001              1.07         0.036                                              1.24         \< 0.001                        
  8         5,6-Dihydroxyindole                    1.72         0.014                                                                                                              1.85         \< 0.001
  9         Acetyl-DL-Valine                       1.12         \< 0.001                                           1.10         \< 0.001                                                        
  10        Allopurinol                            2.31         0.002              2.74         \< 0.001           2.09         0.004              3.16         \< 0.001           2.02         0.005
  11        Anigorootin                            1.21         0.029              1.30         0.01               1.03         0.015              1.48         0.002              1.10         0.024
  12        Arachidonic acid                       1.60         0.006                                                                                                                           
  13        Catechin 7-glucoside                   1.54         0.04               1.69         0.008              1.74         0.005              2.11         0.016              1.74         0.009
  14        Cerium                                 1.12         0.014              1.29         0.001              1.29         0.001              1.66         \< 0.001           1.34         0.002
  15        Cytidine monophosphate                 1.09         \< 0.001           1.05         \< 0.001           1.05         \< 0.001                                                        
  16        Deoxycholic acid 3-glucuronide         1.56         \< 0.001           1.27         \< 0.001           1.37         \< 0.001           1.57         \< 0.001           1.18         0.001
  17        Dimethyl D-malate                      1.59         \< 0.001           1.68         \< 0.001           1.24         0.004              1.67         \< 0.001           1.04         0.042
  18        Diphenol glucuronide                   2.69         \< 0.001           2.59         \< 0.001           2.58         \< 0.001           1.74         0.001              2.07         \< 0.001
  19        Glyceric acid                          1.05         0.005              1.60         \< 0.001           1.22         \< 0.001           1.69         \< 0.001           1.33         \< 0.001
  20        Glycerol tribenzoate                   2.56         0.044              2.84         0.008              2.92         0.005              3.42         0.023              2.93         0.008
  21        Hippuric acid                          1.46         0.001                                                                              1.73         \< 0.001           1.49         \< 0.001
  22        Hypoxanthine                           2.67         0.001              1.97         0.048                                              2.90         0.001              2.15         0.005
  23        Indole                                 1.96         0.033              1.27         0.005                                                                              1.85         0.008
  24        Indoxylsulfuric acid                   3.93         \< 0.001                                           3.89         \< 0.001           2.55         0.006              3.32         \< 0.001
  25        L-Phenylalanine                        2.14         0.012              1.21         0.004              2.42         0.007                                              2.19         0.001
  26        L-Tryptophan                           3.23         \< 0.001                                           3.16         \< 0.001           2.63         0.001              2.64         \< 0.001
  27        L-Tyrosine                             1.48         0.027              1.56         0.016              1.60         0.002                                              1.58         0.005
  28        Muramic acid                           2.23         0.03               2.66         0.002              2.53         0.002              3.61         \< 0.001           2.23         0.012
  29        N-Acetyl-[D]{.smallcaps}-glucosamine   1.91         \< 0.001           1.82         \< 0.001           1.81         \< 0.001           2.01         \< 0.001           1.49         \< 0.001
  30        N-Acetyl-L-tyrosine                    1.08         \< 0.001           1.44         \< 0.001                                           1.09         \< 0.001                        
  31        N-Acetylserotonin sulfate              1.16         0.005                                              1.16         0.001              1.26         \< 0.001                        
  32        ND                                     1.87         0.012              2.15         \< 0.001           2.13         0.001              2.69         \< 0.001           2.18         0.002
  33        ND                                     1.70         0.011              1.92         \< 0.001           1.86         0.001              2.46         \< 0.001           2.01         0.001
  34        ND                                     1.50         0.012              1.69         0.001              1.65         0.001              2.17         \< 0.001           1.77         0.002
  35        ND                                     1.30         0.044              1.44         0.008              1.47         0.005              1.79         0.017              1.48         0.009
  36        Oleic acid                             2.14         0.005                                                                              2.13         0.035              1.97         0.002
  37        PGE3                                   1.51         \< 0.001           1.61         0.001              1.38         \< 0.001           1.50         \< 0.001           1.17         0.002
  38        Prostaglandin A1                       1.08         \< 0.001           1.19         \< 0.001           1.01         \< 0.001           1.13         \< 0.001                        
  39        PS(21:0/0:0)                           2.90         \< 0.001           2.37         \< 0.001           2.56         \< 0.001           2.92         \< 0.001           2.17         0.001
  40        Purine                                 1.18         \< 0.001           1.34         \< 0.001           1.14         \< 0.001           1.15         \< 0.001                        
  41        Pyrocatechol sulfate                   1.48         \< 0.001           1.25         0.013              1.38         \< 0.001                                           1.25         0.001
  42        Selenomethionine                       1.75         0.001              2.18         \< 0.001           1.66         \< 0.001           2.28         \< 0.001           1.77         \< 0.001
  43        Stearoyllactic acid                    1.24         0.013              1.27         0.015                                              1.35         0.027              1.08         0.006
  44        Thiamine                               1.22         \< 0.001                                           1.12         \< 0.001           1.07         \< 0.001                        
  45        Uridine                                2.10         \< 0.001           2.58         \< 0.001           2.13         \< 0.001           3.13         \< 0.001           2.18         \< 0.001
  46        18-Hydroxyarachidonic acid                                             1.12         0.031                                              1.22         0.034              2.37         \< 0.001
  47        Dithionous acid                                                        1.10         0.004                                              1.02         \< 0.001                        
  48        D-Lactic acid                                                          5.62         0.005              5.95         0.004                                              4.87         0.043
  49        Formamide                                                              1.27         0.004              1.12         0.002                                                           
  50        Isoplumbagin                                                           1.13         \< 0.001           1.08         \< 0.001           1.05         \< 0.001                        
  51        L-Threonine                                                            2.03         0.011              1.74         0.01               1.22         0.004              2.02         \< 0.001
  52        Succinic acid                                                          1.53         \< 0.001           1.23         \< 0.001           1.02         \< 0.001           1.36         \< 0.001
  53        N-acetylaspartate                                                                                                                      1.84         0.001              1.56         0.001
  54        2-hydroxy-2-methyl-butyric acid                                        1.03         \< 0.001                                                                                        
  55        Glucaric acid                                                          1.08         0.008                                                                                           
  56        MG\[18:2(9Z,12Z)/0:0/0:0\]                                             1.03         0.002                                                                                           
  57        Deoxyuridine                                                                                           1.24         0.003                                                           
  58        PGE3                                                                                                   1.38         \< 0.001                                                        
  59        PE(18:0/14:0)                                                                                          1.45         \< 0.001                                                        
  60        (±)9-HODE                                                                                                                              1.17         \< 0.001                        
  61        (E)-13-Octadecenoic acid                                                                                                               1.01         0.041                           
  62        ADP-glucose                                                                                                                            1.27         \< 0.001                        
  63        Adrenosterone                                                                                                                          1.06         \< 0.001                        
  64        Avenoleic acid                                                                                                                         1.16         \< 0.001                        
  65        Deoxyinosine                                                                                                                           1.17         \< 0.001                        
  66        L-Arginine                                                                                                                             1.27         \< 0.001                        
  67        ND                                                                                                                                     1.13         \< 0.001                        
  68        β-Alanine                                                                                                                              1.08         \< 0.001                        
  69        Cholic acid glucuronide                                                                                                                                                1.60         \< 0.001
  70        LysoPE\[18:2(9Z,12Z)/0:0\]                                                                                                                                             1.00         0.03
  71        Myristoylglycine                                                                                                                                                       1.07         0.001
  72        Palmitoleic acid                                                                                                                                                       1.04         0.008
  73        Sinapinic acid-O-sulfate                                                                                                                                               1.06         \< 0.001

a

Compared 1 w post-infection group with control group;

b

Compared 2 w post-infection group with control group;

c

Compared 3 w post-infection group with control group;

d

Compared 4 w post-infection group with control group; and

e

Compared 5 w post-infection group with control group. ND: not identified.

Pathway Enrichment Analysis of Serum Metabolic Profiles {#S3.SS5}
-------------------------------------------------------

As shown in [Table 1](#T1){ref-type="table"}, there were total 73 serum metabolites changed by *S. japonicum* infection over 5 weeks, which indicated that *S. japonicum* infection has disturbed the normal biological process in mice. In order to reveal the disturbed biological process, these identified serum metabolites were imported into **MetaboAnalyst 3.5** for functional enrichment analysis, and the detailed results were shown in [Figure 3](#F3){ref-type="fig"}. 73 serum metabolites were mainly involved in aspartate metabolism, thiamine metabolism, glycerolipid metabolism, pyrimidine metabolism, pyruvaldehyde degradation, cardiolipin biosynthesis, trehalose degradation, phenylalanine and tyrosine metabolism, phosphatidylethanolamine biosynthesis, taurine and hypotaurine metabolism, ketone body metabolism, thyroid hormone synthesis, starch and sucrose metabolism, phosphatidylcholine biosynthesis, and phosphatidylinositol phosphate metabolism, etc.

![Schematic overview of the disturbed metabolic pathways associated with *Schistosoma japonicum* infection. Each node represents a metabolic pathway with its color based on its *p* value, and its size is based on fold enrichment to your query. Two pathways are connected by an edge if the number of their shared metabolites is over 25% of the total number of their combined metabolites.](fmicb-11-01517-g003){#F3}

Of all these 73 candidate metabolites in the above analysis, seventeen serum metabolites were finally screened and identified at all the five post-infection time points, including diphenol glucuronide, [D]{.smallcaps}-glucuronic acid, cerium, glycerol tribenzoate, catechin 7-glucoside, PS(21:0/0:0), N-Acetyl-[D]{.smallcaps}-glucosamine, PGE3, deoxycholic acid 3-glucuronide, uridine, selenomethionine, muramic acid, allopurinol, glyceric acid, 1-methylinosine, anigorootin, and dimethyl D-malate. The detailed data was listed in [Table 2](#T2){ref-type="table"}. And the levels of these metabolites were associated with the worm-burdens. In general, all the fluctuation trends can be classified into six categories, which is shown in [Figure 4](#F4){ref-type="fig"}. The six trend types are important for uncovering the mechanism of *S. japonicum* infection and need to be deep mined and discussed in detail. Furthermore, pathway analysis with **MetaboAnalyst 3.5** revealed that the whole process of *S. japonicum* infection was involved in pentose and glucuronate interconversions, selenoamino acid metabololism, glycerolipid metabolism, glyoxylate and dicarboxylate metabolism, starch and sucrose metabolism, amino sugar and nucleotide sugar metabolism, pyrimidine metabolism, and glycine, serine and threonine metabolism, which were shown in [Figure 5](#F5){ref-type="fig"}.

###### 

Seventeen potential biomarkers identified at all five post-infection time points.

  **No.**   **Mzmed**   **RT (min)**   **Compound**                           **Related pathway**                           **Trend ^1\ w/0\ *w*^**   **Trend ^2\ w/1\ w^**   **Trend ^3\ w/2\ w^**   **Trend ^4\ w/3\ w^**   **Trend ^5\ w/4\ w^**   **Type**
  --------- ----------- -------------- -------------------------------------- --------------------------------------------- ------------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------
  1         321.04      0.73           Diphenol glucuronide                   ND                                            ↓                         ↑                       ↓                       ↑                       ↓                       A
  2         193.04      4.96           [D]{.smallcaps}-Glucuronic acid        Pentose and glucuronate interconversions      ↓                         ↓                       ↓                       ↓                       ↑                       B
                                                                              Starch and sucrose metabolism                                                                                                                                           
  3         174.83      1.80           Cerium                                 ND                                            ↓                         ↓                       ↑                       ↓                       ↓                       C
  4         449.17      1.10           Glycerol tribenzoate                   Glycerolipid metabolism                       ↓                         ↓                       ↓                       ↑                       ↓                       D
  5         451.17      1.10           Catechin 7-glucoside                   ND                                            ↓                         ↓                       ↓                       ↑                       ↓                       
  6         279.04      1.58           Uridine                                Pyrimidine metabolism                         ↓                         ↓                       ↑                       ↓                       ↑                       E
  7         195.99      3.65           Selenomethionine                       Selenoamino acid metabolism                   ↓                         ↓                       ↑                       ↓                       ↑                       
  8         286.06      5.38           Muramic acid                           Amino sugar metabolism                        ↓                         ↓                       ↑                       ↓                       ↑                       
  9         135.03      3.95           Allopurinol                            Bile secretion                                ↓                         ↓                       ↑                       ↓                       ↑                       
  10        105.02      3.70           Glyceric acid                          Glycine, serine and threonine metabolism      ↓                         ↓                       ↑                       ↓                       ↑                       
                                                                              Glycerolipid metabolism                                                                                                                                                 
                                                                              Glyoxylate and dicarboxylate metabolism                                                                                                                                 
  11        281.04      1.60           1-Methylinosine                        RNA biosynthesis                              ↓                         ↓                       ↑                       ↓                       ↑                       
  12        573.13      5.37           Anigorootin                            ND                                            ↓                         ↓                       ↑                       ↓                       ↑                       
  13        207.05      4.07           Dimethyl D-malate                      Citric acid cycle                             ↓                         ↓                       ↑                       ↓                       ↑                       
  14        566.35      9.31           PS(21:0/0:0)                           Phospholipid metabolism                       ↓                         ↑                       ↓                       ↓                       ↑                       F
  15        256.06      3.44           N-Acetyl-[D]{.smallcaps}-glucosamine   Amino sugar and nucleotide sugar metabolism   ↓                         ↑                       ↓                       ↓                       ↑                       
  16        385.18      1.24           PGE3                                   Arachidonic acid metabolism                   ↓                         ↑                       ↓                       ↓                       ↑                       
  17        567.35      9.31           Deoxycholic acid 3-glucuronide         Bile acid metabolism                          ↓                         ↑                       ↓                       ↓                       ↑                       

A, B, C, D, E, and F: means six types of changing trends. ND: No metabolic pathways involved in this metabolite were found in this study.

![**(A)** The concentration changes of Diphenol glucuronide in *S. japonicum* infection mice. **(B)** The concentration changes of D-Glucuronic acid in *S. japonicum* infection mice. **(C)** The concentration changes of Cerium in *S. japonicum* infection mice. **(D)** The concentration changes of Glycerol tribenzoate and Catechin 7-glucoside in *S. japonicum* infection mice. **(E)** The concentration changes of Uridine, Selenomethionine, Muramic acid, allopurinol, Glyceric acid, 1-Methylinosine, Anigorootin, Dimethyl D-malate in *S. japonicum* infection mice. **(F)** The concentration changes of PS, PGE3, N-Acetyl-D-glucosamine, Deoxycholic acid 3-glucuronide in *S. japonicum* infection mice.](fmicb-11-01517-g004){#F4}

![The pathway impact of *S. japonicum* infection based on the seventeen serum metabolites with MetaboAnalyst 3.5. Colors varying from yellow to red means the metabolites are in the data with different levels of significance.](fmicb-11-01517-g005){#F5}

Discussion {#S4}
==========

Advantages of LC-MS-Based Metabolic Profiling of *S. japonicum* Infection at Early Stage {#S4.SS1}
----------------------------------------------------------------------------------------

To the best of our knowledge, most of the previous metabolomic studies of *schistosoma* infections have been established on the end point of one schistosome life cycle when eggs have been produced. Only one investigation based on the ^1^H NMR spectroscopy in conjunction with multivariate data analysis has been reported which was focused on revealing the time-course metabonomic changes in the *S. japonicum* infection ([@B47]). This ^1^H NMR-based study has revealed metabolic changes from the third week post-infection in biofluids and liver samples, which means that the detection of infection can be achieved 1 week earlier than the current "gold standard" method. During this period, *S. japonicum* worms has not reached maturity or they won't begin to lay eggs until around 4 weeks post-infection ([@B46]). Furthermore, their studies indicated that the variations in metabolic profiles induced by the infection occurred before the sexual maturation of *S. japonicum* worms in the mammalian host and was thus prior to liver injuries by deposition of schistosomal eggs. In contrast to this study, our investigation based on LC-MS technology, as shown in [Figure 2A](#F2){ref-type="fig"}, has revealed that the metabolic changes occurred from the first week post-infection in serum samples. This finding led to the detection of infection can be achieved 2 weeks and 3 weeks earlier than the previously reported ^1^H NMR-based metabolomic method and the current "gold standard" method, respectively. Therefore, the above mentioned findings from our study make it possible for the development of an early diagnostic tool for *S. japonicum* infection. Moreover, a total of 73 metabolites were identified and shown significant changes in metabolic profiles which were associated with the *S. japonicum* infection. The number of metabolites related to the infection we identified was almost two or three folds of those identified in the ^1^H NMR-based method. Our work has successfully demonstrated the usefulness of LC-MS-based metabolomics in parasitic infection studies. Furthermore, due to its high sensitivity, high-throughput, high resolution and good analytical flexibility, the LC-MS-based metabolomics method is well suitable for the comprehensive analysis of large number of metabolites and is superior to all other currently used analytical tools in this field.

Disturbed Metabolic Pathways Associated With *S. japonicum* Infection {#S4.SS2}
---------------------------------------------------------------------

With the established LC-MS-based metabolomics method, we were able to identify a total of 73 metabolites with significant changes after *S. japonicum* infection. These metabolites were used to map on the metabolic pathways perturbed by the *S. japonicum* infection in mice model. To better understand the biological processes related to the infection, we performed pathway enrichment analysis based on these 73 serum metabolites. [Figure 3](#F3){ref-type="fig"} showed the enriched metabolic pathways associated with *S. japonicum* infection, which include the pathways involved in amino acid metabolism (aspartate metabolism, thyroid hormone synthesis), glucose uptake and metabolism (thiamine metabolism, trehalose degradation, taurine and hypotaurine metabolism, and starch and sucrose metabolism), phospholipid metabolism (glycerolipid metabolism, phosphatidylethanolamine biosynthesis, cardiolipin biosynthesis, phosphatidylcholine biosynthesis, and phosphatidylinositol phosphate metabolism), DNA and RNA biosynthesis (pyrimidine metabolism), energy metabolism (ketone body metabolism, pyruvaldehyde degradation), and gut microbiota ecology (phenylalanine and tyrosine metabolism). Liver injury is the typical symptom of *S. japonicum* infection in humans ([@B48]) and the disturbance of amino acid metabolism is one of the metabolic consequences of liver injury. Our findings regarding amino acid metabolism is consistent with the previous study. Another metabolic consequence of liver injury is the stimulated glycolysis, which was reflected by the remarkable reduction of glucose level in plasma following 5 weeks of infection ([@B47]). Interestingly, metabolite taurine, a cell membrane stabilizer and a potential conjugate with bile acid, was also found to be down-regulated after infection in our study, which was consistent with findings from other groups about the liver injury can cause decrease of taurine-conjugated bile acid production and further malabsorption in human with schistosomes infection ([@B47]; [@B48]). Phospholipids are playing important roles in maintaining the integrity and biological activities of liver cell membrane ([@B34]; [@B38]), the changes of phospholipid metabolism discovered in this study may imply the abnormalities of liver cell. All these metabolic findings showed the signs of liver dysfunction caused by *S. japonicum* infection in mice model. In order to promote their survial and transmission, Schistosomes have developed a very complex life cycle with discrete stages perfectly adapted to their differing hosts and free-living environments ([@B42]). Biological processes such as multiplication and proliferation in schistosomes are highly energy consuming, which are entirely reliant on the hosts for the essential nutrients required for development, reproduction and metabolism, For example, the blood flukes can take up glucose from their mammalian hosts and utilize its subsequent metabolism to fuel growth and fecundity ([@B50]). Again, the changes in glucose uptake and metabolism found in our study are correlated with infection progression and disease severity. Lipid metabolism is reported to be associated with the renewal of membrane complex, which is one of most abundant molecules present on the Schistosoma surface. Enough evidence has shown that lipids are essential in the life cycle of the parasite and they are playing an important role in the promotion of membrane fusion with the host resulting in the parasite acquisition of host membrane components. Moreover, these components are reported to have immune modulation properties and involved in maintaining lipid homeostasis in parasitic infection condition ([@B8]). Schistosomiasis is a disease caused predominantly by the host immune response to eggs and granulomatous reaction they evoke ([@B34]; [@B5]). The phospholipid metabolism may be closely related to the host's immune response during parasitic infection. To our knowledge, thyroid hormones (TH) is essential for the regulation of growth, development and differentiation and they are actively involved in many metabolic processes by interacting with thyroid hormone receptors (THR) in the host ([@B29]). Previous studies suggest that TH probably act indirectly or via pathways not involving the control of gene transcription for growth and development ([@B7]). Therefore, the disturbed thyroid hormone synthesis found in our study is clearly consistent with these previous results, and these findings may provide important insights into the mechanism underlying host-parasite interactions during infection. Thiamine, also named Vitamin B1, is involved in the glucose metabolism and catabolism, and has a protective effect for nervous system. In this study, the thiamine metabolism was found to be disturbed after infection, which may suggest the possible abnormality in nervous system and the further confirmation of the disturbed glucose metabolism by schistosome infection in mice. Reports have been shown that gut microbiome can utilize phenylalanine and tyrosine to produce numerous metabolites that may regulate immune, metabolic, and neuronal responses at local and distant sites ([@B25]). The phenylalanine and tyrosine metabolism was also enriched in our study, which may indicate disturbance of the gut microbial ecology after schistosome infection, and this finding is consistent with the previous studies ([@B20]). Carboxylic acids, as the representatives of carbohydrate intermediary metabolism of both aerobic and anaerobic pathways, are directly linked to energy production and metabolism in both the host and the parasite ([@B1]). While another central carbon metabolism, glycolysis, was reported to be the main energy resources for the parasite ([@B47]; [@B28]). Lactic acid, as a product of glycolysis, was found to be significantly higher in the serum of infected mice than in control mice, indicating that the glycolytic pathway of the infected mice was activated. This finding is also consistent with previous research conclusion that lactate was increased in schistosomiasis patients ([@B23]). However, there is a difference in the conclusion that the host's TCA cycle is inhibited after schistosomiasis infection ([@B36]; [@B2]). One of the TCA cycle intermediates, succinic acid, was found to be elevated in the serum of infected mice in this study, but the increase was not as strong as that of lactic acid. Except for this discrepancy, all other results indicated the active involvement of energy metabolism in the host reaction to the *S. japonicum* infection. In addition, pyrimidine metabolism was reported to play important roles in DNA and RNA biosynthesis ([@B37]; [@B51]), therefore the changes in pyrimidine metabolism we identified in this study may suggest the potential effects on DNA and RNA biosynthesis caused by *S. japonicum* infection in mice.

Potential Biomarkers for Early Diagnosis of *S. japonicum* Infection {#S4.SS3}
--------------------------------------------------------------------

As shown in [Table 2](#T2){ref-type="table"}, seventeen serum metabolites were finally screened and identified at all the five post-infection time points in this study. Although there are some fluctuations during the infection cycle, this may be associated with the worm-burdens and progression or the severity of the infections. In general, these metabolites were all decreased at five post-infection time points compared to the pre-infection groups. Notably, as shown in [Figure 4](#F4){ref-type="fig"}, there was a significant decrease at the first week after *S. japonicum* infection. These changes could be indicative of the onset signals for the infection and these metabolites could be potential biomarkers for early diagnosis of *S. japonicum* infection. As reported in the previous study, uridine as a pyrimidine nucleoside, is the material basis of RNA synthesis, the bioavailability of which is particularly crucial to the synthesis of RNA and bio-membranes and the post-translational modification of protein (via the formation of pyrimidine nucleoside-lipid conjugates/UDP-sugar conjugates; [@B21]; [@B6]; [@B37]). Uridine was also reported to exert protective effects against hepatotoxicity ([@B51]). Therefore, the reduction of uridine in our study may indicate that the DNA and RNA synthesis was disturbed in the host and liver toxicity was induced by the infection ([@B53]). It was reported that selenomethionine plays an important role in preventing oxidative stress and improving cell viability ([@B3]). Herein, the reduction of selenomethionine in our results may suggest that the stress status was induced in the host by infection. Phosphatidylserine (PS) was reported to play important roles in cellular apoptosis, and attract macrophages to engulf actions during tissue damage ([@B14]). Prostaglandin E3 (PGE3) as one of 3-series prostaglandin compounds, is the product of eicosapentaenoic acid (EPA) through cyclooxygenases (COXs) and possesses an anti-inflammatory effect ([@B49]; [@B45]; [@B11]). Cerium is also reported to exert anti-inflammatory and antioxidant effect ([@B32]). As reported in the previous studies, parasite infection can lead to the formation of ROS and further contribute to oxidative stress in the host. Thus, the reduction of PGE3 and Cerium may be the consequences of its overuse to relieve inflammation. The reduction of catechin 7-glucoside, diphenol glucuronide, [D]{.smallcaps}-glucuronic acid and deoxycholic acid 3-glucuronide can reflect the disturbed phase II metabolism under infection condition, and the reduced phase II metabolism further confirmed the liver damage caused by infection. In addition, glyceric acid and glycerol tribenzoate are related with phospholipid synthesis, and phospholipid are essential membrane components for Schistosomes ([@B34]). Dimethyl D-malate is the dimethyl conjugate of malate, which is the TCA cycle intermediates. Therefore, the reduction of phospholipid and TCA cycle intermediates may be the consequences of the overuse by parasites and induced by the activation of glycolysis. As a bacterial marker, muramic acid can serve as a core structural element for innate immune recognition of peptidoglycan (PG) fragments ([@B24]), the reduction of which may indicate the change in immune response in host after infection. Furthermore, pathway analysis with **MetaboAnalyst 3.5** revealed that these potential biomarkers are mainly involved in pentose and glucuronate interconversions, selenoamino acid metabololism, glycerolipid metabolism, glyoxylate and dicarboxylate metabolism, starch and sucrose metabolism, amino sugar and nucleotide sugar metabolism, pyrimidine metabolism, and glycine, serine and threonine metabolism (shown in [Figure 5](#F5){ref-type="fig"}). In summary, these involved pathways provide more insightful understandings of the potential metabolic process associated with schistosomiasis. Furthermore, our findings on these mechanisms of host-parasite interaction during the disease process pave the way for the development of an early diagnosis tool.
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